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Received 11 August 2012; accepted 23 August 2012More than 6 decades have passed since the report of hy-
pogammaglobulinemia, the first well-characterized primary
immunodeficiency disease (PID), was published.1 However,
clinicians and medical researchers are still constantly
amazed by the new developments in this group of complex
and often fatal diseases. With the rapid increase of
knowledge in clinical immunology, new entities of PID arise
with a fast pace.2 At the same time, deeper understanding
of the immunodeficiency diseases continues to reveal key
immunological facts. These novel discoveries from
researches on patients with PID also facilitate the devel-
opment of new clinical tools to benefit these patients with
increased susceptibility to pathogenic microorganisms.3
At least 176 hereditary entities have been described in
this group of diseases and many of them are clinically
apparent from an early age.4 Like most inheritable
diseases, PIDs have been traditionally known as the
devastating diseases caused by mutations on key functional
proteins, which lead to total or nearly total loss of immune
defense. However, more complex immunopathogenic
mechanisms have been found to impede immune* Corresponding author. Institute of Clinical Medicine, National
Cheng-Kung University, 138 Sheng-Li Road, Tainan 70403, Taiwan.
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http://dx.doi.org/10.1016/j.jmii.2012.08.023responses against specific microorganisms and lead to
subtle or late-onset immunodeficiencies in otherwise
“healthy” individuals.
Adult-onset immunodeficiency in Asia
A study by Browne et al on patients in Taiwan and Thailand
recently revealed an example of a late-onset immunodefi-
ciency more prevalent in people of Southeastern Asian
origin.5 The HIV-negative adult patients in that study were
found to have predisposition to infections by non-
tuberculous mycobacteria alone or with other opportunistic
infections (e.g. fungi including Cryptococcus neoformans,
Histoplasma capsulatum, Penicillium marneffei, and
bacteria including Salmonella spp.). Although the patients
had adequate CD4þ T lymphocytes (>350/ml) and the
washed leukocytes had intact cytokine production in
response to cytokine stimulation, their plasma inhibited
in vitro IFN-g detection and activity of IFN-g on normal
cells. High-titer anti-IFN-g autoantibodies occurred in
around 90% of the groups with disseminated NTM but in only
2% of the control groups.5 Although autoantibodies against
proinflammatory cytokines including IFN-g, IL-17A, IL-17F,
and IL-22 have been reported previously6,7 and several case
reports describing such patients have been published
before,8 the recent study by Browne et al5 is the mostished by Elsevier Taiwan LLC. All rights reserved.
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presumably more prevalent in Southeast Asia, which is
a region less intensively investigated regarding immuno-
deficiencies before.Approaches to pinpoint subtle leukocyte
function defects with molecular diagnosis
Early diagnosis of infection from both host and pathogen
sides are crucial for successful treatment. However, the
presentation of infections in patients with subtle immuno-
deficiencies may challenge the conventional wisdom of
clinical diagnosis. As exemplified in a study published in this
issue of JMII by Wang et al, the subtle initial clinical
presentation in patients with nonoverwhelming immuno-
deficiency may be localized and prolonged in the course of
their infections.9 However, without accurate diagnosis and
timely treatment, the infection can become disseminated
and debilitating. As reported by Wang et al, in these
patients who have been denied a diagnosis for up to 10
years, measurement of cytokines, detection of leukocyte
surface receptors and DNA sequencing of suspected genes
were accomplished rapidly and led to the diagnosis of
Mendelian susceptibility to mycobacterial diseases. More-
over, the development of array methods to detect disease-
causing microorganisms enabled the clinicians to treat the
patients effectively and in a timely manner. The successful
molecular diagnoses in both host and pathogen sides high-
light the feasibility of novel diagnostic methods in clinical
care of PID patients. Given the recent increase in number of
reports on molecular characterization of immune responses
to difficult infections,10,11 we can reasonably expect that
the detection of subtle immunodeficiency will become
more common in the near future.PID: Under-reported and under-treated
Although various forms of registry of PID have been ongoing
for decades in the nations such as the United States, France,
United Kingdom, Japan, and Taiwan,12,13 estimation of
prevalence or incidence based on these registries have been
in doubt since most of these registries have to rely on
voluntary reporting of physicians. Based on a community-
wide survey, a nationwide random telephone survey in
the USA, and data from registries for PID, Bousfiha et al
estimated the prevalence of PID may be 6 million world-
wide, whereas only 27,000 (all national registries) to 60,000
(the Jeffrey Modell Centers Network) have been identified
to date in registries.14 Even in Europe, only 2.27% of the
patients are currently registered. Moreover, PID were
prevalent not only in children, but also in adults. The
registry rate of PID in adults, due the lower awareness of PID
in adult physicians, was even lower. If their estimations are
close to the truth, the prevalence and incidence of PIDs are
similar to those observed for diseases such as leukemia.14
The discrepancy between the estimated numbers of
patients and those who are clinically registered might
explain many reported unusual infections that may lead
to treatment failure in presumably immune-competent
patients.9,15 Considering the severe personal sufferingand potential cost of treatment for difficult infections,
diagnosis of non-HIV induced immunodeficiencies should be
pursued diligently. Systematic and dedicated epidemiolog-
ical studies on PID are therefore required to obtain essential
information for clinically significant immunodeficiencies
especially in Eastern Asian countries, which are less exten-
sively explored regarding the occurrence of PID.
Immunodeficiency in the age of personalized
medicine
By extending our understanding of the pathophysiology of
immunodeficiency from phenomenology to cellular and
subcellular mechanisms, we have increased our ability to
manipulate the immune responses to the patients’ benefit.
Development of diagnostic tools in regions other than
United States and Europe has enabled us to identify PID
rarely seen in the more developed countries. This will no
doubt broaden the scope of the understanding on human
PID and will prove to be crucial for the subtle modification
for treatment for immune-relevant diseases in the new age
of personalized medicine.
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